Firstly, current studies on cardiomyopathy-induced PANoptosis primarily rely on simultaneous detection of apoptosis markers (e.g., cleaved Caspase-3), pyroptosis markers (e.g., GSDMD-N), and necroptosis markers (e.g., p-MLKL) as evidence of PANoptosis activation. This evidence concerns the gene MLKL and cardiomyopathy.